A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group (A-PART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00646412
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : September 9, 2015
Information provided by (Responsible Party):
Aesculap AG

March 25, 2008
March 28, 2008
September 9, 2015
July 2008
May 2010   (Final data collection date for primary outcome measure)
Occurrence of wound healing impairment and/or postoperative peritonitis after surgery [ Time Frame: 28 (+10) days ]
Same as current
Complete list of historical versions of study NCT00646412 on Archive Site
  • Occurrence of anastomosis leakage after surgery [ Time Frame: within 28 (+10) days ]
  • Occurrence of adverse events (AEs) and serious adverse events (SAEs) after surgery [ Time Frame: postoperative hospital stay and up to 3 months ]
  • Adhesion rates along the scar examined by ultrasound-assessment [ Time Frame: 14 days (range: day 7-14), 28 days (+10 days), 3 months (± 14 days) ]
Same as current
Not Provided
Not Provided
A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group
A Prospective, Randomised, Controlled, Single-blind Phase I-II Clinical Trial on the Safety of A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group
The safety of applying A-Part® Gel intra-peritoneally under the incision in order to prevent post-surgical adhesions after median laparotomy.

Primary Objective:

• first assessment of the safety of applying A-Part® Gel as adhesion prophylaxis after major abdominal surgery by specific observation of two major complications of abdominal surgery (wound healing impairment, and/or postoperative peritonitis) in comparison to a control group.

Secondary Objectives:

  • To further evaluate the safety of A-Part® Gel by comparing the incidences of adverse events between the treatment groups (with special attention to anastomosis leakage)
  • To explore the efficacy of A-Part® Gel in reducing post-surgical adhesions after median laparotomy
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
  • Adhesions
  • Abdominal Cavity
Device: A-Part® Gel
10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
  • Experimental: A
    A-Part® Gel
    Intervention: Device: A-Part® Gel
  • No Intervention: B
    untreated control group

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
August 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients of both sexes, who are candidates for a primary and elective median abdominal incision with a length of ≥ 15 cm 2.
  • Age ≥ 18 years
  • Patients who are legally capable and able to understand the nature, significance and consequences of the study and are willing and able to comply with the study protocol and the follow up
  • Written informed consent obtained according to international guidelines and local law. Informed consent will be documented by the volunteer's dated signature, which will be also signed and dated by the investigator
  • Patients with an expected survival time >12 months
  • For female adults of reproductive potential: Negative pregnancy test at visit 1 and sufficient contraception from time of written consent up to at least 4 months

Exclusion Criteria:

  • Patients with a previous median laparotomy and any other abdominal surgery (exceptions: previous laparoscopic appendectomy, cholecystectomy, inguinal hernia repair, gynecological tube sterilisation)
  • Patients with a known history of adhesions or a known history of peritonitis
  • Patients with a known sensitivity to polyvinylalcohol and/or carboxymethylcellulose
  • Simultaneous participation of the patient in another clinical trial or participation in a clinical trial within the last 30 days prior to signing the Informed consent form
  • Patients with ASA > 3 or emergency patients (including severe psychic diesease)
  • Patients with ascites > 200 ml
  • Patients with peritoneal carcinosis or peritoneal dialysis
  • Patients with a diagnosed peritonitis, intra-abdominal abscess or other intra-abdominal infection
  • Patient with renal impairment (Creatinine > 1.3 mg/dl)
  • Patients with systemic immunosuppression (e.g. hydrocortisone > 50mg daily [oral/i.v.] at any day or any equivalent dosage; other immunosuppressants like Azathioprin, Mycophenolatmofetil, Ciclosporin, Everolimus, Methotrexat, ect.), chemotherapy or radiotherapy within the last 2 weeks prior to surgery
  • Surgical procedures or patient characteristics which require insertion of more than 2 intra-abdominal drainages
  • Women within a pregnancy or breast-feeding mothers or women who wish to get pregnant within the next 4 months after surgery or women without sufficient contraceptive care
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Aesculap AG
Aesculap AG
Not Provided
Principal Investigator: Karl-Walter Jauch, Prof.Dr. Chirurgische Klinik und Poliklinik - Großhadern, Klinikum der Universität München
Aesculap AG
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP